Dyadic International Earnings Call Highlights Early Momentum

Dyadic International Inc. ((DYAI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Dyadic International’s latest earnings call struck a cautiously optimistic tone, highlighting sharp year-over-year revenue growth and a flurry of new product launches, while underscoring that the company is still in an early commercialization phase. Management emphasized operational progress, partner validation and a solid cash runway, but acknowledged ongoing losses, rising costs and execution risks as key watchpoints for investors.

Strong Revenue Growth

Dyadic reported Q1 2026 revenue of about $1.1 million, a 182% jump from roughly $394,000 a year ago, reflecting accelerating commercial and collaboration activity. The increase was driven by around $220,000 in R&D revenue from the Proliant agreement, about $277,000 in grant revenue from CEPI and Gates programs, and roughly $200,000 in milestone revenue under the Inzymes agreement.

Commercial Product Launches and Shipments

The quarter saw multiple products move into commercial channels, signaling early traction across several verticals. Proliant launched Albufree Dx with Dyadic eligible for profit-sharing, Inzymes commercialized recombinant bovine chymosin, Fermbox EN3ZYME fulfilled a large commercial order, and Dyadic launched animal-origin-free DNase-1 alongside shipments of DNase-1 and bovine transferrin to IBT Bioservices.

Distribution and Partner Expansion

Dyadic expanded its go-to-market reach through new and broadened distribution partnerships that leverage external channels instead of heavy internal sales build-out. A global OEM distribution deal with IBT Bioservices and an enlarged Intralink agreement now covering Europe, after success in Japan, are expected to accelerate sampling and customer qualification while keeping fixed costs relatively contained.

Grant Funding and Biopharma Validation

Non-dilutive funding remains a core pillar of Dyadic’s strategy, supporting both revenue and technical validation of its C1 platform. Programs backed by a roughly $3 million Gates grant and up to about $2.4 million from CEPI continue to advance monoclonal antibody and vaccine antigen work, producing data that management says show comparability to traditional CHO-derived antibodies.

Platform Clinical and Preclinical Data

The company highlighted growing evidence that its C1 platform is de-risked for human use, which is key for attracting larger biopharma partners. Dyadic has completed a Phase I human study demonstrating safety for a C1-produced protein and has generated nonhuman primate data with C1-produced monoclonal antibodies, positioning the platform for expanded, partner-led therapeutic opportunities.

Early Commercial Traction in Target Markets

Beyond biopharma, Dyadic is seeing initial traction in food, nutrition and bioindustrial markets that could provide diversified growth. The company has received first purchase orders for recombinant bovine transferrin for cultivated meat and cell culture, is advancing a BRIG BIO collaboration on bovine alpha-lactalbumin with sampling targeted for mid-2026, and is expanding sampling activity for bioindustrial products in the Asia Pacific region.

Improved Operating Losses and Cash Discipline

Despite being unprofitable, Dyadic showed incremental progress on the bottom line while stressing disciplined cash use. Loss from operations improved about 5% year over year to roughly $1.9 million, net loss narrowed to around $1.95 million or $0.05 per share from about $2.03 million or $0.07 per share, and the company ended Q1 with approximately $6.6 million in cash and securities.

Multiple Revenue Pathways

Management underscored that Dyadic’s business model is designed around several revenue levers rather than a single blockbuster product. Current and potential income streams include direct product sales, OEM distribution, profit-sharing, milestones, licensing and various partnerships across life sciences, food and nutrition and bioindustrial markets, which could smooth volatility as individual programs progress.

Rising Cost of Revenue

The flip side of rapid activity growth is a sharp rise in cost of revenue, which investors will watch closely for margin trends. Total cost of revenue climbed to about $792,000 in Q1 2026 from roughly $298,000 a year earlier, an increase of around 166%, largely tied to expanded R&D and grant-funded program work under the CEPI and Gates initiatives.

G&A Expense Increase

Operating expenses also ticked higher, reflecting both growth investments and unavoidable compliance costs. General and administrative expenses rose by about $159,000, or 10% year over year, to roughly $1.8 million as higher legal and accounting fees and rebranding and business development efforts more than offset lower share-based compensation and insurance savings.

Continued Net Losses and Modest Scale

While topline growth is strong in percentage terms, Dyadic remains far from breakeven, a key risk factor for shareholders. The company posted a net loss of about $1.95 million for the quarter, and absolute revenue of roughly $1.1 million remains modest, highlighting that the business is still in an early scale-up phase with significant operating leverage yet to be realized.

Early-Stage, Grant-Heavy Revenue Mix

Investors should note that a sizable share of current revenue is tied to non-recurring or project-based sources rather than mature product sales. R&D reimbursements, grant funding and milestone recognition contributed meaningfully in Q1, while anticipated royalties and larger partner-derived revenues are still in the pipeline and had not yet fully materialized in the period.

Gradual Ramp for Key Products

Management tempered expectations for a rapid inflection in product sales, particularly for recombinant bovine transferrin. Current orders are at small kilogram pilot volumes and the company expects a steady rather than explosive ramp, with significant volume growth dependent on regulatory progress and commercialization timelines in cultivated meat and other cell culture-driven applications.

Dependence on Partners and Outsourced Execution

Dyadic’s asset-light commercialization strategy leans heavily on partners for manufacturing and distribution, which lowers capital needs but adds execution risk. Key relationships with Fermbox, IBT, Intralink and BRIG BIO are central to scaling product sales, yet they also limit Dyadic’s direct control over rollout timing, pricing and ultimate margins across its target markets.

Cash Position and Potential Financing Needs

The company’s cash balance provides a multi-year runway, but the call signaled that management remains open to new capital if commercialization lags. With about $6.6 million in cash and an expected 2026 burn similar to or below last year’s less than $5.7 million, Dyadic projects liquidity into the second quarter of 2027 while continuing to evaluate strategic partnerships and capital markets options.

Guidance and Outlook

For the near term, Dyadic reiterated its expectation that product revenue will grow through the rest of 2026, supported by IBT-distributed DNase-1 and transferrin shipments and the first bioindustrial royalties. The company plans to keep operating expenses largely in line with 2025 levels, while cost of revenue and internal R&D, which was about $476,000 and down 4% year over year in Q1, should track activity levels as more programs progress toward commercialization.

Dyadic’s earnings call painted the picture of a platform company moving from proof-of-concept into early commercialization, with promising growth but still meaningful execution and funding risks. Investors will watch how quickly grants and milestones convert into recurring product sales, how margins evolve as volumes scale and whether the company can maintain its cash discipline while unlocking the upside from its diversified partnership-driven model.